Pimavanserin, either alone or in conjunction with a selective serotonin reuptake inhibitor or serotonin–norepinephrine reuptake inhibitor, may improve comorbid depression symptoms in patients with Parkinson disease.
To learn more about SEP-363856 as a novel treatment for schizophrenia, we spoke with Kenneth Koblan, PhD, and John Krystal, MD.
Compared to the general population, patients with Parkinson disease report a higher prevalence of ophthalmologic symptoms.
Researchers assessed the effect of isradipine on clinical progression in previously untreated patients with early-stage PD.
High-intensity exercise training may improve sleep parameters in patients with Parkinson disease.
Telephone-based cognitive behavioral therapy seems to be an effective intervention for depression in Parkinson disease, outperforming treatment-as-usual on all depression, anxiety, and quality-of-life measures.
Patients with Parkinson disease tend to have an increase in iron content with reduced perfusion in the substantia nigra.
Up to half of patients with Parkinson disease are also diagnosed with dementia, but tools to track changes in cognition are lacking.
Patients with Parkinson disease have a higher prevalence of ophthalmologic symptoms than controls.
Stress-related disorders are associated with an increased risk for neurodegenerative diseases.